Daniel B. Soland, Director at KalVista Pharmaceuticals, Inc. (KALV), bought 17,962 shares at $11.87 ($213K) on 2019-09-27, disclosed to the SEC on 2019-09-30.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.90 | 2,038 | $24K | 11.4% |
| 2 | $11.87 | 7,962 | $95K | 44.3% |
| 3 | $11.87 | 7,962 | $95K | 44.3% |
| Total | $11.87 avg | 17,962 | $213K | 100% |
| Filing → |
| IDRA | BUY | 2021-03-05 | $39K | — | Filing → |
| ACAD | BUY | 2018-03-02 | $235K | — | Filing → |
| VPHM | SELL | 2012-03-06 | $990K | — | Filing → |